Skip to main content

Metastatic Adenocarcinoma of the Pancreas clinical trials at UCSF
1 in progress, 0 open to new patients

  • GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).

    San Francisco, California and other locations